Graft-versus-host disease cost-effectiveness of therapy

Graft-versus-host disease
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Graft-versus-host disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Graft-versus-host disease cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Graft-versus-host disease cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Graft-versus-host disease cost-effectiveness of therapy
CDC on Graft-versus-host disease cost-effectiveness of therapy
Graft-versus-host disease cost-effectiveness of therapy in the news
Blogs on Graft-versus-host disease cost-effectiveness of therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Graft-versus-host disease cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]

Overview

Cost-effectiveness of therapy focuses on the use of balance of medical expenses and therapeutic efficacy. In the case of GvHD therapy, corticosteroids are the least expensive treatment option, and alternative immunosuppressants or biologics are more expensive.

Cost-Effectiveness of Therapy

Corticosteroids are the most cost-effective therapy for GvHD. Prednisone and methylprednisolone are available at very low cost. If corticosteroids can be used, these should be given first. Second-line therapies such as alternative immunosuppressants are significantly more expensive. The most expensive therapies include biologics (such as antibodies) and cell-based therapies such as mesenchymal stem cell therapy.